



**In the Claims:**

This listing of claims replaces all prior versions of claims in the application:

1. (Currently amended) A compound having structure I or II as indicated below:



(I)



(II)

wherein:

R1<sup>-</sup> represents ~~[[an]]~~ a pharmaceutically acceptable anion associated with the positive charge of the N atom;

R2 is selected from the group consisting of cycloalkyl groups having from 5 to 6 carbon atoms, cycloalkyl-alkyl having 6 to 10 carbon atoms, heterocycloalkyl having 5 to 6 carbon atoms and N or O as the heteroatom, heterocycloalkyl-alkyl having 6 to 10 carbon atoms and N or O as the heteroatom, aryl, ~~optionally substituted aryl,~~ heteroaryl, ~~and optionally substituted heteroaryl;~~ and

Z is a bond or (C<sub>1</sub>-C<sub>6</sub>)alkyl.

2. (Original) A compound according to claim 1 wherein R1<sup>-</sup> is selected from the group consisting of chloride, bromide, iodide, sulfate, benzene sulfonate and toluene sulfonate.

3. (Cancelled)

4. (Currently amended) A compound according to claim ~~[[3]]~~ 1 selected from the group consisting of:

3-(2-Hydroxy-2,2-di-thiophen-2-yl-ethylidene)-8,8-dimethyl-8-azonia-bicyclo[3.2.1]octane iodide;

USSN 10/575,837

Art Unit: 1625

3-(2-Benzyl-2-hydroxy-3-phenyl-propylidene)-8,8-dimethyl-8-azonia-bicyclo[3.2.1]octane iodide; and

3-(2-Hydroxy-2,2-diphenyl-ethylidene)-8,8-dimethyl-8-azonia-bicyclo[3.2.1]octane iodide.

5. (Currently amended)      A pharmaceutical composition ~~for the treatment of muscarinic acetylcholine receptor mediated diseases~~ comprising a compound according to claim 1 and a pharmaceutically acceptable carrier thereof.

6. to 13. (cancelled)

14. (new)      A compound according to Claim 1 wherein R<sub>2</sub> is heteroaryl.

15. (new)      A compound according to Claim 14 wherein R<sub>2</sub> is thienyl.

16. (new)      A compound according to Claim 15 wherein Z is a bond.

17. (new)      A compound according to Claim 1 wherein R<sub>2</sub> is aryl.


18. (new)      A compound according to Claim 17 wherein R<sub>2</sub> is phenyl.

19. (new)      A compound according to Claim 18 wherein Z is a (C<sub>1</sub>-C<sub>6</sub>)alkyl.

20. (new)      A compound according to Claim 19 wherein Z is a (C<sub>1</sub>)alkyl.

21. (new)      A compound according to Claim 18 wherein Z is a bond.

22. (new) A compound having structure II as indicated below:



(II)

wherein:

R1<sup>-</sup> represents a pharmaceutically acceptable anion associated with the positive charge of the N atom;

R2 is selected from the group consisting of cycloalkyl groups having from 5 to 6 carbon atoms, cycloalkyl-alkyl having 6 to 10 carbon atoms, heterocycloalkyl having 5 to 6 carbon atoms and N or O as the heteroatom, heterocycloalkyl-alkyl having 6 to 10 carbon atoms and N or O as the heteroatom, aryl and heteroaryl; and

Z is a bond or (C<sub>1</sub>-C<sub>6</sub>)alkyl.

23. (new) A compound according to claim 21 wherein R1<sup>-</sup> is selected from the group consisting of chloride, bromide, iodide, sulfate, benzene sulfonate and toluene sulfonate.

24. (new) A compound according to claim 21 selected from the group consisting of:

2-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-ylidene)-1,1-di-thiophen-2-yl-ethanol;

2-Benzyl-1-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-ylidene)-3-phenyl-propan-2-ol; and

2-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-ylidene)-1,1-diphenyl-ethanol.

25. (new) A compound according to Claim 21 wherein R2 is heteroaryl.

26. (new) A compound according to Claim 25 wherein R2 is thienyl.

27. (new) A compound according to Claim 26 wherein Z is a bond.

28. (new) A compound according to Claim 1 wherein R2 is aryl.

29. (new) A compound according to Claim 28 wherein R<sub>2</sub> is phenyl.
30. (new) A compound according to Claim 29 wherein Z is a (C<sub>1</sub>-C<sub>6</sub>)alkyl.
31. (new) A compound according to Claim 30 wherein Z is a (C<sub>1</sub>)alkyl.
32. (new) A compound according to Claim 29 wherein Z is a bond.
33. (new) A compound according to claim 21 wherein R<sub>1</sub><sup>-</sup> is selected from the group consisting of chloride, bromide, iodide, sulfate, phosphate, methanesulfonate, ethane sulfonate, acetate, malate, tartrate, citrate, lactate, oxalate, succinate, fumarate, maleate, benzoate, salicylate, phenyl acetate, and mandelate.
34. (new) A pharmaceutical composition comprising a compound according to claim 21 and a pharmaceutically acceptable carrier thereof.
35. (new) A pharmaceutical composition comprising a compound according to claim 24 and a pharmaceutically acceptable carrier thereof.
36. (new) A pharmaceutical composition comprising a compound according to claim 4 and a pharmaceutically acceptable carrier thereof.
37. (new) A compound according to claim 1 wherein R<sub>1</sub><sup>-</sup> is selected from the group consisting of chloride, bromide, iodide, sulfate, phosphate, methanesulfonate, ethane sulfonate, acetate, malate, tartrate, citrate, lactate, oxalate, succinate, fumarate, maleate, benzoate, salicylate, phenyl acetate, and mandelate.